New cord blood treatment aims to speed recovery in tough blood cancers
NCT ID NCT07301866
First seen Jan 06, 2026 · Last updated May 10, 2026 · Updated 19 times
Summary
This study tests a lab-grown cord blood transplant boosted with a higher dose of UM171 for adults with high-risk blood cancers like leukemia who lack a suitable donor. The goal is to help blood counts recover faster, reduce infections, and shorten hospital stays. Only 7 participants will be enrolled and followed for one year after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA, HIGH RISK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Maisonneuve-Rosemont
RECRUITINGMontreal, Quebec, H1T 2M4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.